Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Experimental: YB-101
YB-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| YB-101 | EXPERIMENTAL | In Part 1, participants will receive YB-101 via subcutaneous injection. Part 2 participants will receive YB-101 via subcutaneous injection. |
| Placebo YB-101 | PLACEBO_COMPARATOR | In Part 1, participants will receive placebo via subcutaneous injection. Part 2 participants will receive placebo via subcutaneous injection. |
| Name | Type | Description |
|---|---|---|
| Experimental: YB-101 | DRUG | YB-101 is administered over a 24 week period. |
| Placebo YB-101 | DRUG | Placebo will be administered over a 24 week period. |
Inclusion Criteria: * Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment * Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmol...
YB-101 is an investigational small molecule being developed by Yarrow Bioscience, Inc. for the treatment of Graves' Disease, an endocrine condition. It is currently in Phase 2 clinical development and has not been approved by the FDA. YB-101 is also referred to in study materials as Experimental: YB-101.
YB-101 is being evaluated as a treatment for Graves' Disease, an autoimmune endocrine disorder. It is an investigational therapy in Phase 2 testing and is not yet approved for any indication. The ongoing trial is assessing its safety, tolerability, pharmacokinetics, and efficacy in adults with the condition.
YB-101 targets TSHR, the thyroid-stimulating hormone receptor. TSHR belongs to the antibody target class. By acting on this receptor, YB-101 is designed to interfere with the receptor pathway implicated in Graves' Disease. The drug is a small molecule in Phase 2 development.
YB-101 is being developed by Yarrow Bioscience, Inc., which trades under the ticker YARW. The company is running a Phase 2 clinical program for the drug in Graves' Disease. Yarrow Bioscience is the sole developer listed for this asset.
YB-101 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 2 trial is currently recruiting participants and is designed to evaluate safety, tolerability, pharmacokinetics, and efficacy in Graves' Disease.
YB-101 is being studied in one active clinical trial, NCT07682896, titled Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease. The Phase 2 trial is recruiting 232 participants across the United States and Australia. It is randomized, double-blind, and placebo-controlled, enrolling adults 18 years and older.